These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31780303)

  • 1. Neurological soft signs in schizophrenia spectrum disorders are not confounded by current antipsychotic dosage.
    Fritze S; Sambataro F; Kubera KM; Bertolino AL; Topor CE; Wolf RC; Hirjak D
    Eur Neuropsychopharmacol; 2020 Feb; 31():47-57. PubMed ID: 31780303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
    Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
    Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Minor neurological and physical anomalies in patients with first-episode psychosis].
    Mhalla A; Boussaïd N; Gassab L; Gaha L; Mechri A
    Encephale; 2013 Jun; 39(3):149-54. PubMed ID: 23095597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurologic soft signs and olanzapine treatment in chronic schizophrenia.
    Sevincok L; Topaloglu B; Kiyilioglu N
    J Clin Psychopharmacol; 2004 Oct; 24(5):571-2. PubMed ID: 15349026
    [No Abstract]   [Full Text] [Related]  

  • 5. 12-Month stability of neurological soft signs in stabilized patients with schizophrenia.
    Fountoulakis KN; Panagiotidis P; Kimiskidis V; Nimatoudis I
    Nord J Psychiatry; 2019 Oct; 73(7):451-461. PubMed ID: 31393751
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk factors, pre-morbid functioning and episode correlates of neurological soft signs in drug-naive patients with schizophrenia-spectrum disorders.
    Peralta V; de Jalón EG; Campos MS; Basterra V; Sanchez-Torres A; Cuesta MJ
    Psychol Med; 2011 Jun; 41(6):1279-89. PubMed ID: 20860873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurological soft signs in early onset schizophrenia].
    Bourgou Gaha S; Halayem Dhouib S; Amado I; Bouden A
    Encephale; 2015 Jun; 41(3):209-14. PubMed ID: 24854724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurological soft signs in schizophrenic patients and their nonaffected siblings].
    Mechri A; Slama H; Bourdel MC; Chebel S; Mandhouj O; Krebs MO; Gaha L
    Encephale; 2008 Oct; 34(5):483-9. PubMed ID: 19068337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.
    Gebhardt S; Härtling F; Hanke M; Theisen FM; von Georgi R; Grant P; Mittendorf M; Martin M; Fleischhaker C; Schulz E; Remschmidt H
    Eur Child Adolesc Psychiatry; 2008 Feb; 17(1):44-53. PubMed ID: 17876506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia.
    Halstead SM; Barnes TR; Speller JC
    Br J Psychiatry; 1994 Feb; 164(2):177-83. PubMed ID: 7909711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological soft signs in first-episode schizophrenia: State- and trait-related relationships to psychopathology, cognition and antipsychotic medication effects.
    Emsley R; Chiliza B; Asmal L; Kilian S; Riaan Olivier M; Phahladira L; Ojagbemi A; Scheffler F; Carr J; Kidd M; Dazzan P
    Schizophr Res; 2017 Oct; 188():144-150. PubMed ID: 28130002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurological soft signs discriminate schizophrenia from major depression but not bipolar disorder.
    Zhao Q; Ma YT; Lui SS; Liu WH; Xu T; Yu X; Tan SP; Wang ZR; Qu M; Wang Y; Huang J; Cheung EF; Dazzan P; Chan RC
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():72-8. PubMed ID: 23266480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of activation procedures on neuroleptic-induced akathisia.
    Fleischhacker WW; Miller CH; Barnas C; Bergmann K; Perovich R; Alvir JM; Lieberman JA; Kane JM
    Br J Psychiatry; 1993 Dec; 163():781-4. PubMed ID: 7905775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential contributions of brainstem structures to neurological soft signs in first- and multiple-episode schizophrenia spectrum disorders.
    Fritze S; Bertolino AL; Kubera KM; Topor CE; Schmitgen MM; Wolf RC; Hirjak D
    Schizophr Res; 2019 Aug; 210():101-106. PubMed ID: 31178363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depression measures and motor side-effects in patients with acute schizophrenia.
    Kontaxakis VP; Havaki-Kontaxaki BJ; Stamouli SS; Margariti MM; Kollias CT; Christodoulou GN
    Schizophr Res; 2002 Jul; 56(1-2):197-8. PubMed ID: 12084435
    [No Abstract]   [Full Text] [Related]  

  • 17. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving forward: distinct sensorimotor abnormalities predict clinical outcome after 6 months in patients with schizophrenia.
    Sambataro F; Fritze S; Rashidi M; Topor CE; Kubera KM; Wolf RC; Hirjak D
    Eur Neuropsychopharmacol; 2020 Jul; 36():72-82. PubMed ID: 32522386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.
    Kopala LC; Good KP; Honer WG
    J Clin Psychopharmacol; 1997 Aug; 17(4):308-13. PubMed ID: 9241011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects.
    Kim JH; Byun HJ
    Clin Neuropharmacol; 2003; 26(6):312-6. PubMed ID: 14646611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.